HER2 MUTANT NON-SMALL CELL LUNG CANCER

HER2 MUTANT NON-SMALL CELL LUNG CANCER was reported 11 times

HER2 MUTANT NON-SMALL CELL LUNG CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] 1 0.0002
1 HER2/neu Receptor Antagonist [EPC] 4 0.0001
2 Vascular Endothelial Growth Factor Inhibitor [EPC] 6 0.0000
3 Platinum-based Drug [EPC] 6 0.0000
4 Folate Analog Metabolic Inhibitor [EPC] 6 0.0000
5 Topoisomerase Inhibitor [EPC] 1 0.0000
6 Microtubule Inhibitor [EPC] 2 0.0000
7 Programmed Death Receptor-1 Blocking Antibody [EPC] 1 0.0000
8 Kinase Inhibitor [EPC] 5 0.0000